Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease
Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients
Objective: To describe patient demographic and medication utilization patterns within a state Medicaid program for patients diagnosed with Parkinson’s disease (PD). Background: Little is known…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Ceftriaxone improves motor function in a rat hemi-parkinsonian model: Potential to delay bilateral progression of motor deficits in Parkinson’s disease
Objective: This study sought to evaluate the impact of ceftriaxone, as a potential repurposed drug, in ameliorating motor decline in a unilateral rat 6-hydroxydopamine (6-OHDA)…The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease
Objective: The nanoherbaceutical formulation comprising natural L-DOPA from Mucuna pruriens against rotenone caused Parkinson's disease in rats to be prepared and evaluated. Background: Parkinson's disease…Correlation Between Dyskinesia and Quality of Life at Baseline and After 12 months of Treatment with LCIG in Patients with Advanced Parkinson’s Disease
Objective: Evaluate the correlation between dyskinesia and quality of life (QoL) at baseline and after 12 months of treatment with levodopa-carbidopa intestinal gel (LCIG) in…High Satisfaction and Improved Quality of Life with Rock Steady Boxing in Parkinson’s Disease
Objective: To compare demographics, self-reported symptom burden, Health-Related Quality of Life (HRQL), and Exercise Self-Efficacy (ESE) between Rock Steady Boxing (RSB) participants and non-participants. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.